Ampio Pharmaceuticals, Inc.

AMPEOTCHealthcare● Active

$0.18

+$0.00(+0.00%)

Market Cap$207884

P/E Ratio—

52W High$0.6435

52W Low$0.0001

Avg Volume154

Open$0.01

Beta6.07

Free Cash Flow Financials Revenue

Ampio Pharmaceuticals, Inc. (AMPE) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

AMPE · free cash flow · updated Jun 8, 2026

Core FCF metrics

AMPE · FCF · TTM · margin & CAGR

Free cash flow was −$8.6M for FY2023 (fiscal year ending 2023-12-31), up 59.5% year-over-year

FY2023 Free Cash Flow−$8.6M▲ +59.5% YoY

Trailing 12M (TTM)−$8.6Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

AMPE · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2023Latest−$8.6M(0M)−$8.6M▲ +59.5%—

FY2022−$21.1M(0M)−$21.1M▼ 48.9%—

FY2021−$14.1M(0M)−$14.2M▲ +4.1%—

FY2020−$14.7M(0M)−$14.8M▲ +4.0%—

FY2019−$15.4M(0M)−$15.4M▼ 21.3%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

AMPE · P/FCF · FCF yield · FCF per share

Ampio Pharmaceuticals, Inc. (AMPE) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2023 · 2023-12-31

Cash flow statement summary

AMPE · cash flow statement · operating / investing / financing

For FY2023, Ampio Pharmaceuticals, Inc. generated −$8.6M in operating cash flow and spent 0M in capital expenditures, yielding −$8.6M in free cash flow.

Operating Activities

−$8.6M

Cash from core business operations

2023-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2023-12-31

Financing Activities

+$0.0M

Buybacks, dividends & debt

2023-12-31

FCF FormulaOperating CF (−$8.6M) − |CapEx| (0M) = FCF (−$8.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

AMPE vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Ampio Pharmaceuticals, Inc.YOU

AMPE

−$8.6M+59.5%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Ampio Pharmaceuticals, Inc. (AMPE) reported free cash flow of −$8.6M for FY2023 (fiscal year ending 2023-12-31), up 59.5% year-over-year.

Ampio Pharmaceuticals, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

AMPE free cash flow · 8 questions

Ampio Pharmaceuticals, Inc. free cash flow was −$8.6M for FY2023, up 59.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$8.6M.

AMPE free cash flowAMPE FCFAMPE FCF 2023AMPE free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Ampio Pharmaceuticals, Inc. · Ampio Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026